Hypertension in long-term survivors of pediatric hematopoietic cell transplantation

Biol Blood Marrow Transplant. 2010 Apr;16(4):515-24. doi: 10.1016/j.bbmt.2009.11.018. Epub 2009 Dec 2.

Abstract

A retrospective study was conducted to determine risk factors for the development of hypertension (HTN) and to describe the prevalence among long-term survivors of pediatric hematopoietic cell transplant (HCT). Records of 689 pediatric patients who survived 5 years or more after HCT, from 1969 to 2004, were reviewed for development of HTN. In children, HTN was defined as either a systolic or diastolic pressure > or =95th percentile according to age, sex, and height. In adults, HTN was defined as systolic pressures > or =140 mmHg and/or diastolic pressures > or =90 mmHg in nondiabetic adults and systolic pressures > or =130 and/or diastolic pressures > or =80 in diabetic adults. Multivariate Cox regression models were used to estimate the hazard ratio (HR) of risk factors associated with HTN. All patients included were off immunosuppressive therapy. Patients had been treated with total body irradiation (TBI) (n = 482, 70%) or non-TBI regimens (n = 207, 30%) followed by autologous (n = 87), related (n = 484), or unrelated donor HCT (n = 118). Median follow-up was 16 (range: 5-36) years. HTN developed in 120 patients with a 30-year cumulative incidence of 36%. Risk factors associated with HTN were acute kidney injury (AKI; doubling of baseline creatinine by day 100 after HCT) (HR = 2.5; 95% confidence interval (CI) 1.7-3.7, P < .0001), TBI in the preparative regimen (HR = 2.1; 95% CI 1.3-3.3, P = .001), donor type (autologous HR = 2.4; 95% CI 1.3-4.4 and unrelated donor HR = 1.8; 95% CI 1.0-3.2, P = .01), obesity (HR = 4.0; 95% CI 2.3-6.8, P < .0001), diabetes (HR = 6.7; 95% CI 3.9-11.0, P < 0.0001), and history of growth hormone therapy (HR = 1.6; 95% CI 1.0-2.5, P = .05). Patients with a positive history of hepatitis C infection were less likely to develop HTN (HR = 0.5; 95% CI 0.3-0.9, P = .009). Prevalence of HTN was 15% overall and among survivors 11-17 years and 18-39 years old, the prevalence was 10% and 14% or triple and double that of the general U.S. population, respectively. Pediatric HCT survivors are more likely to develop HTN than the general population and should be monitored for HTN throughout adulthood.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Child
  • Child, Preschool
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Hypertension / etiology*
  • Hypertension / therapy
  • Incidence
  • Infant
  • Male
  • Multivariate Analysis
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • Survival Rate
  • Survivors